Inactive Instrument

Press Releases Akcea Therapeutics, Inc.

Equities

AKCA

US00972L1070

Press Releases

Unlock all the news: Be the first to know and act before the market!

Ionis Pharmaceuticals : Akcea Therapeutics - WAYLIVRA, the first and only therapy for familial chylomicronaemia syndrome, to be available on the NHS in Scotland	10/20/10	AQ
Ionis Pharmaceuticals : and Akcea Recognize FCS Awareness Day with Global Community Efforts to Celebrate Unsung Heroes	09/20/09	AQ
IONIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	05/20/05	AQ
Ionis Pharmaceuticals : and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen	04/20/04	AQ
Ionis Pharmaceuticals : and Akcea win prestigious Prix Galien Award for TEGSEDI as Best Biotechnology Product	02/20/02	AQ
Ionis Pharmaceuticals : completes acquisition of Akcea Therapeutics	13/20/13	AQ
AKCEA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	13/20/13	AQ
IONIS PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits (form 8-K)	13/20/13	AQ
Akcea Therapeutics : Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics	12/20/12	PR
Akcea Therapeutics : WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England	18/20/18	BU
WeissLaw LLP Reminds AKCA and AIMT Shareholders About Its Ongoing Investigations	12/20/12	PR
AKCEA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akcea Therapeutics, Inc. - AKCA	05/20/05	BU
AKCEA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	01/20/01	AQ
IONIS PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	31/20/31	AQ
Akcea Therapeutics : Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics	31/20/31	PR
Akcea Therapeutics : and Ionis to Present Phase 2 Clinical Data of Vupanorsen at ESC Congress 2020	25/20/25	AQ
Akcea Therapeutics : Announces New Pricing and Reimbursement of WAYLIVRA in Germany	14/20/14	AQ
AKCEA THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	06/20/06	AQ
Akcea Therapeutics: 2Q Earnings Snapshot	05/20/05	AQ
Akcea Therapeutics : Reports Financial Results and Highlights for Second Quarter 2020	05/20/05	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Akcea Therapeutics, Inc.

Equities

AKCA

US00972L1070

Press Releases

Filters